[HTML][HTML] Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent …
R Groß, M Zanoni, A Seidel, C Conzelmann, A Gilg… - …, 2022 - thelancet.com
Background Heterologous COVID-19 vaccination regimens combining vector- and mRNA-based
vaccines are already administered, but data on solicited adverse reactions, …
vaccines are already administered, but data on solicited adverse reactions, …
[HTML][HTML] An enzyme-based immunodetection assay to quantify SARS-CoV-2 infection
C Conzelmann, A Gilg, R Groß, D Schuetz, N Preising… - Antiviral Research, 2020 - Elsevier
SARS-CoV-2 is a novel pandemic coronavirus that caused a global health and economic
crisis. The development of efficient drugs and vaccines against COVID-19 requires detailed …
crisis. The development of efficient drugs and vaccines against COVID-19 requires detailed …
[HTML][HTML] Computational modeling and experimental validation of the EPI-X4/CXCR4 complex allows rational design of small peptide antagonists
EPI-X4, a 16-mer fragment of albumin, is a specific endogenous antagonist and inverse
agonist of the CXC-motif-chemokine receptor 4 (CXCR4) and thus a key regulator of CXCR4 …
agonist of the CXC-motif-chemokine receptor 4 (CXCR4) and thus a key regulator of CXCR4 …
[HTML][HTML] An optimized derivative of an endogenous CXCR4 antagonist prevents atopic dermatitis and airway inflammation
Aberrant CXCR4/CXCL12 signaling is involved in many pathophysiological processes such
as cancer and inflammatory diseases. A natural fragment of serum albumin, named EPI-X4, …
as cancer and inflammatory diseases. A natural fragment of serum albumin, named EPI-X4, …
[HTML][HTML] Microtiter plate-based antibody-competition assay to determine binding affinities and plasma/blood stability of CXCR4 ligands
CXC chemokine receptor type 4 (CXCR4) is involved in several intractable disease processes,
including HIV infection, cancer cell metastasis, leukemia cell progression, rheumatoid …
including HIV infection, cancer cell metastasis, leukemia cell progression, rheumatoid …
[HTML][HTML] Advanced EPI-X4 derivatives covalently bind human serum albumin resulting in prolonged plasma stability
…, A Heck, YB Ruiz-Blanco, A Gilg… - International Journal of …, 2022 - mdpi.com
Advanced derivatives of the Endogenous Peptide Inhibitor of CXCR4 (EPI-X4) have shown
therapeutic efficacy upon topical administration in animal models of asthma and dermatitis. …
therapeutic efficacy upon topical administration in animal models of asthma and dermatitis. …
Advanced molecular tweezers with lipid anchors against SARS-CoV-2 and other respiratory viruses
…, C Conzelmann, JA Müller, L Rauch, A Gilg… - JACS Au, 2022 - ACS Publications
The COVID-19 pandemic caused by SARS-CoV-2 presents a global health emergency.
Therapeutic options against SARS-CoV-2 are still very limited but urgently required. Molecular …
Therapeutic options against SARS-CoV-2 are still very limited but urgently required. Molecular …
[HTML][HTML] The C-terminal 32-mer fragment of hemoglobin alpha is an amyloidogenic peptide with antimicrobial properties
…, V Vogel, L Cortez Rayas, R Groß, A Gilg… - Cellular and Molecular …, 2023 - Springer
Antimicrobial peptides (AMPs) are major components of the innate immune defense.
Accumulating evidence suggests that the antibacterial activity of many AMPs is dependent on the …
Accumulating evidence suggests that the antibacterial activity of many AMPs is dependent on the …
Development of N-Terminally Modified Variants of the CXCR4-Antagonistic Peptide EPI-X4 for Enhanced Plasma Stability
M Harms, R Fabech Hansson, A Gilg… - Journal of Medicinal …, 2023 - ACS Publications
EPI-X4, a natural peptide CXCR4 antagonist, shows potential for treating inflammation and
cancer, but its short plasma stability limits its clinical application. We aimed to improve the …
cancer, but its short plasma stability limits its clinical application. We aimed to improve the …
Macromolecular Viral Entry Inhibitors as Broad‐Spectrum First‐Line Antivirals with Activity against SARS‐CoV‐2
Inhibitors of viral cell entry based on poly(styrene sulfonate) and its core–shell nanoformulations
based on gold nanoparticles are investigated against a panel of viruses, including …
based on gold nanoparticles are investigated against a panel of viruses, including …